Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Hypertensive Patients and a Comparison of the Effects of Amlodipine and Ramipril on TAFI Levels


Özkan G., ULUSOY Ş. , SÖNMEZ M. , KARAHAN S. C. , MENTEŞE A. , KAYNAR K., ...Daha Fazla

CLINICAL AND EXPERIMENTAL HYPERTENSION, cilt.35, ss.134-140, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 35 Konu: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.3109/10641963.2012.702833
  • Dergi Adı: CLINICAL AND EXPERIMENTAL HYPERTENSION
  • Sayfa Sayıları: ss.134-140

Özet

Hypertension is associated with fibrinolysis abnormality. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a novel molecule-linking coagulation and fibrinolysis. The aim of this study was to investigate the levels of TAFI in primary hypertensive patients and to compare the effects of amlodipine and ramipril on TAFI levels. The study was performed with 58 hypertensive subjects and 27 healthy volunteers. Biochemical and hematological parameters and TAFI levels were measured at baseline and after 1-month follow-up. TAFI concentrations increased in hypertensive patients compared with the controls (P = .030). Additionally, TAFI levels decreased with blood pressure control at 1-month follow-up (P = .026). There was no significant difference between TAFI levels in the amlodipine and ramipril groups at baseline. However, after 1-month follow-up, TAFI levels were decreased in the amlodipine group (P = .037) but not in the ramipril group. Our study is the first in the literature to determine increased TAFI levels in primary hypertension patients. In addition, we determined a decrease in TAFI levels in the amlodipine group after 1 month, but none in the ramipril group.